from The American Heritage® Dictionary of the English Language, 4th Edition
- adj. Of or relating to the period of a disease before the appearance of symptoms.
from Wiktionary, Creative Commons Attribution/Share-Alike License
- adj. Describing the period of a disease before any symptoms appear
- adj. Describing a test or trial of a new pharmaceutical on animals (or in vitro) rather than on humans
from WordNet 3.0 Copyright 2006 by Princeton University. All rights reserved.
- adj. of or relating to the early phases of a disease when accurate diagnosis is not possible because symptoms of the disease have not yet appeared
Roche said Intermune's experimental medicine danoprevir "has shown promising efficacy in preclinical and early clinical development" and should "increase flexibility" to develop and market Roche's portfolio of drugs against hepatitis C, an infection of the liver that affects around 180 million people worldwide.
In addition, Array has completed long-term preclinical regulated safety studies and has identified a commercially viable synthetic process and oral formulation for ARRY-162.
In addition, the Company has completed long-term preclinical regulated safety studies and has identified a commercially viable synthetic process and oral formulation for ARRY-162.
They also added a new research category called preclinical Alzheimer's, the earliest stage of the disease when clumps of amyloid start to form in the brains of people who are otherwise healthy.
Just over a third are in preclinical, that is not a surprise, there are a lot of shots on goal.
It is entirely possible that more such foods can be developed, but each will either be an outgrowth of traditional practices confirmed by usage, or will require the kind of preclinical and clinical testing described in PAG Guidelines 6, 7, and 12 (7 -
BioCryst Pharmaceuticals surged 44 cents, or 12%, to 4.11, after the company announced positive results from a preclinical trial of its potential treatment of hepatitis C.
It has two main businesses: preclinical services, which assists companies with laboratory, toxicology and related resources; and research models and services, which supports companies in early-stage drug research.
Sales for the research-models segment were $159.3 million in the third quarter, down 2.5% from a year earlier, while sales for the preclinical services division were $116.8 million, down 13%.
By contrast, preclinical animal trials assessing the therapeutic efficacy of cannabinoids are occurring at a record pace.